Venous thromboembolism (VTE) is a common complication of cancer. Prolonged use of low‑molecular‑weight heparin in cancer patients provides better VTE prophylaxis compared with vitamin K antagonists. Both therapeutic options have a similar safety profile. If patients on long‑term oral anticoagulation are diagnosed with cancer, they should continue treatment with vitamin K antagonists.